The FDA typically follows the recommendations of its advisory panels but is not required to do so. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind ...
Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...
Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single ...
Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...
Developed in partnership with agency Wieden+Kennedy Portland, Lilly’s Good Days officially launched on Sunday. The spot will air in the final slot before showings of Wicked: For Good and during the ...
6hon MSN
Is Eli Lilly a buy before 2026?
Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...
INDIANAPOLIS — Indiana University and pharmaceutical giant Eli Lilly have made official a five-year collaboration in which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback